AHA/ACC提出临床数据标准化定义

2015-01-16 中国循环杂志 微信

刀币、布币、环钱……,秦统一前各诸侯国的钱币可谓形态各异,这大大阻碍了当时的经济发展。当前,收集上来的临床数据也是凌乱的,同样羁绊了医学前进的脚步。 为了构建更为优良的数据环境,美国心脏病学院(ACC)/美国心脏协会(AHA)的临床数据标准工作组与美国食品药品管理局(FDA)和心血管试验标准数据采集联盟(SCTI)合作阐述了关于“为临床试验和健康相关研究制定通用语言迈步”的标准。

刀币、布币、环钱……,秦统一前各诸侯国的钱币可谓形态各异,这大大阻碍了当时的经济发展。当前,收集上来的临床数据也是凌乱的,同样羁绊了医学前进的脚步。

为了构建更为优良的数据环境,美国心脏病学院(ACC)/美国心脏协会(AHA)的临床数据标准工作组与美国食品药品管理局(FDA)和心血管试验标准数据采集联盟(SCTI)合作阐述了关于“为临床试验和健康相关研究制定通用语言迈步”的标准。

临床数据标准化,就是力求界定和规范化相关临床数据概念,使其具有良好的一致性、精确性和重复性,这样才能便于管理。

在这份报告中,心血管终点定义为心血管原因导致的死亡、心肌梗死、因不稳定性心绞痛住院、一过性脑缺血发作(TIA)、脑卒中、心力衰竭事件、经皮冠脉介入治疗、外周血管治疗以及支架血栓形成等。

“因不稳定性心绞痛住院”,必须包括存在心电图异常,如ST段的改变等客观指标。

很多病因都可导致心力衰竭,对心力衰竭事件的定义为“基本治疗策略失败后必须给予强化治疗”。

“我们希望经过这些数据标准化工作能够保证电子病历、临床试验数据、注册研究、药物/器械管理以及相关研究中有关心血管病终点的患者数据尽量一致,从而促进数据的共享。”ACC/AHA临床数据标准工作组主席Karen A. Hicks进一步强调。

此外,他们也考虑到个体健康信息的隐私权,全部纳入数据库的信息都将会受到保护。如果研究者调用相关数据,必须经过相关审查机构首肯。

SCTI工作组由来自学术界、专业学会、FDA以及制药和心血管领域器械生产商的专家组成。ACC/AHA工作组包括16位内科、心脏病学、神经医学、临床研究、流行病学、介入治疗、临床结果评价、医学信息学、健康信息管理以及医疗服务与研究的相关专家。

原始出处:

Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE, Targum SL.2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).J Am Coll Cardiol. 2014 Dec 29. pii: S0735-1097(14)07484-1. doi: 10.1016/j.jacc.2014.12.018. [Epub ahead of print]


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1758781, encodeId=0bd61e5878152, content=<a href='/topic/show?id=9fb76191944' target=_blank style='color:#2F92EE;'>#标准化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61919, encryptionId=9fb76191944, topicName=标准化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Apr 02 04:16:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18587, encodeId=7be41858e6f, content=(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76341618614, createdName=35566569, createdTime=Sat Mar 21 03:52:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016686, encodeId=9c8a20166868a, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Sat Aug 15 11:16:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267251, encodeId=8128126e25158, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jan 18 00:16:00 CST 2015, time=2015-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324989, encodeId=bf2e132498946, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jan 18 00:16:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1758781, encodeId=0bd61e5878152, content=<a href='/topic/show?id=9fb76191944' target=_blank style='color:#2F92EE;'>#标准化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61919, encryptionId=9fb76191944, topicName=标准化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Apr 02 04:16:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18587, encodeId=7be41858e6f, content=(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76341618614, createdName=35566569, createdTime=Sat Mar 21 03:52:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016686, encodeId=9c8a20166868a, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Sat Aug 15 11:16:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267251, encodeId=8128126e25158, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jan 18 00:16:00 CST 2015, time=2015-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324989, encodeId=bf2e132498946, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jan 18 00:16:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2015-03-21 35566569

    (⊙o⊙)

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1758781, encodeId=0bd61e5878152, content=<a href='/topic/show?id=9fb76191944' target=_blank style='color:#2F92EE;'>#标准化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61919, encryptionId=9fb76191944, topicName=标准化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Apr 02 04:16:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18587, encodeId=7be41858e6f, content=(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76341618614, createdName=35566569, createdTime=Sat Mar 21 03:52:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016686, encodeId=9c8a20166868a, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Sat Aug 15 11:16:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267251, encodeId=8128126e25158, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jan 18 00:16:00 CST 2015, time=2015-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324989, encodeId=bf2e132498946, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jan 18 00:16:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1758781, encodeId=0bd61e5878152, content=<a href='/topic/show?id=9fb76191944' target=_blank style='color:#2F92EE;'>#标准化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61919, encryptionId=9fb76191944, topicName=标准化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Apr 02 04:16:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18587, encodeId=7be41858e6f, content=(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76341618614, createdName=35566569, createdTime=Sat Mar 21 03:52:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016686, encodeId=9c8a20166868a, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Sat Aug 15 11:16:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267251, encodeId=8128126e25158, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jan 18 00:16:00 CST 2015, time=2015-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324989, encodeId=bf2e132498946, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jan 18 00:16:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]
    2015-01-18 zhaohui6731
  5. [GetPortalCommentsPageByObjectIdResponse(id=1758781, encodeId=0bd61e5878152, content=<a href='/topic/show?id=9fb76191944' target=_blank style='color:#2F92EE;'>#标准化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61919, encryptionId=9fb76191944, topicName=标准化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Apr 02 04:16:00 CST 2015, time=2015-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18587, encodeId=7be41858e6f, content=(⊙o⊙), beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76341618614, createdName=35566569, createdTime=Sat Mar 21 03:52:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016686, encodeId=9c8a20166868a, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Sat Aug 15 11:16:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267251, encodeId=8128126e25158, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Jan 18 00:16:00 CST 2015, time=2015-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324989, encodeId=bf2e132498946, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jan 18 00:16:00 CST 2015, time=2015-01-18, status=1, ipAttribution=)]

相关资讯

Circulation:AHA发布2015心脏病和卒中统计数据

12 月17 日,《循环(Circulation)杂志在线发表了美国心脏学会(AHA)《心脏病和卒中统计数据(2015更新版)》。新版数据表明,虽然发病率在下降,但心脑血管病的总负担仍很重。数据着重强调了与心脑血管病相关的健康行为方式和健康因素的重要性。 心脑血管 心脑血管疾病负担现状 4种健康相关行为 3大危险因

AHA/ASA评选出心脑血管疾病的2014年十大进展

减重手术治疗2型糖尿病的新证据 STSMPEDE研究随访3年发现:减重手术可改善2型糖尿病肥胖患者血糖水平,并可减少降糖药物的应用,改善生活质量。(N Engl J Med,2014,370:2002-13) 去肾交感神经术治疗顽固性高血压遭质疑 SIMPLICITY HTN-3研究显示:在降压效果上,试验组并不比假手术组好多少。几乎浇灭了人们对去肾交感神经术的热情。

AHA 2014中国研究展示

编者按:作为世界心血管综合性盛会之一,美国心脏学会(AHA)年会是各国心血管医生展示研究成果和与同行交流的舞台。美国芝加哥当地时间11月17日,AHA会议现场展示了如下中国研究。 China PEACE回顾性研究的启示 2014年6月24日,《柳叶刀》杂志在线发表冠心病医疗结果评价和临床转化研究(China PEACE)”主要结果,该研究为改善中国冠心病的临床诊治提供了依据。中国医

AHA 2014:美国心脏学会科学年会亮点一览

2014年美国心脏学会(AHA)科学年会将于11月16日至19日在美国芝加哥隆重举行。今年的会议注重讨论环节,不仅发布最新临床试验,还增强了互动性,形式多样。AHA2014大会主席Robert Harrington博士在欢迎辞中写道,本届大会将围绕心血管领域的7个核心方面展开,覆盖了“基础、转化、临床以及人口科学”四个方面。也将一如既往地快速、全面报道本次学术盛会,敬请关注专题报道。

郭艺芳点评:强效降胆固醇:大剂量他汀还是常规剂量他汀联合依折麦布?(IMPROVE-IT研究)

2014年AHA年会期间揭晓了IMPROVE-IT研究结果。近年来,此研究一直受到广泛期待。之所以如此,是因为这项研究或可回答两个至关重要的问题:(1)降胆固醇是硬道理还是他汀是硬道理?已有充分证据显示,应用他汀降低胆固醇水平可以显著降低心血管病患者及其高危人群不良心血管事件的发生率。但应用其他药物降低胆固醇水平是否产生同样的获益尚不清楚。(2)当LDL-C处于较低水平时继续降低其水平可否进一步获

AHA 2014:缺氧和低血压对外伤性脑损伤有协同负面效应

AHA 2014科学年会的一项报告表明,院前缺氧和低血压可对外伤性脑损伤(TBI)患者产生协同负面效应,导致死亡风险相对于单一因素显著升高3倍以上。14 此项研究共纳入9194例中重度TBI患者,并以氧饱和度<90%定义缺氧,以收缩压<90 mmHg定义低血压。对年龄、性别、种族、付款来源和创伤治疗中心等混淆因素进行校正之后,利用比值比(OR)评估死亡率与缺氧和/或低血压之间